Cost-effectiveness of 10-Year Risk Thresholds for Initiation of Statin Therapy for Primary Prevention of Cardiovascular Disease
about
Consumption of Yogurt and the Incident Risk of Cardiovascular Disease: A Meta-Analysis of Nine Cohort Studies.The Expected Cardiovascular Benefit of Plasma Cholesterol Lowering with or Without LDL-C Targets in Healthy Individuals at Higher Cardiovascular Risk.Strategies for Primary Prevention of Coronary Heart Disease Based on Risk Stratification by the ACC/AHA Lipid Guidelines, ATP III Guidelines, Coronary Calcium Scoring, and C-Reactive Protein, and a Global Treat-All Strategy: A Comparative--EffectiveCan cardiovascular disease guidelines that advise treatment decisions based on absolute risk be improved?Use of low density lipoprotein particle number levels as an aid in statin treatment decisions for intermediate risk patients: a cost-effectiveness analysis.Cost-Effectiveness of Screening for Primary Aldosteronism and Subtype Diagnosis in the Resistant Hypertensive Patients.Recent Update to the US Cholesterol Treatment Guidelines: A Comparison With International Guidelines.2013 ACC/AHA Cholesterol Guideline and Implications for Healthy People 2020 Cardiovascular Disease Prevention Goals.Cost-Effectiveness of LDL-C Lowering With Evolocumab in Patients With High Cardiovascular Risk in the United States.Assessing potential population impact of statin treatment for primary prevention of atherosclerotic cardiovascular diseases in the USA: population-based modelling study.Cost-effectiveness of Evolocumab Therapy for Reducing Cardiovascular Events in Patients With Atherosclerotic Cardiovascular Disease.Clinical implications of the IMPROVE-IT trial in the light of current and future lipid-lowering treatment options.Application of the 2014 NICE cholesterol guidelines in the English population: a cross-sectional analysis.Incident Cardiovascular Disease Among Adults With Blood Pressure <140/90 mm Hg.Validation of a Cardiovascular Disease Policy Microsimulation Model Using Both Survival and Receiver Operating Characteristic Curves.Guideline-based statin/lipid-lowering therapy eligibility for primary prevention and accuracy of coronary artery calcium and clinical cardiovascular events: The Multi-Ethnic Study of Atherosclerosis (MESA).Economic evaluation of ezetimibe treatment in combination with statin therapy in the United States.NORRISK 2: A Norwegian risk model for acute cerebral stroke and myocardial infarction.Cost-effectiveness of diabetes screening initiated through a dental visit.Estimating Longitudinal Risks and Benefits From Cardiovascular Preventive Therapies Among Medicare Patients: The Million Hearts Longitudinal ASCVD Risk Assessment Tool: A Special Report From the American Heart Association and American College of CarImpact of Cigarette Smoking and Smoking Cessation on Life Expectancy Among People With HIV: A US-Based Modeling Study.Comparative effectiveness and cost-effectiveness of treat-to-target versus benefit-based tailored treatment of type 2 diabetes in low-income and middle-income countries: a modelling analysis.Evaluating the Impact and Cost-Effectiveness of Statin Use Guidelines for Primary Prevention of Coronary Heart Disease and Stroke.Dental Status and Compression of Life Expectancy with Disability.Quantifying sociodemographic and income disparities in medical therapy and lifestyle among symptomatic patients with suspected coronary artery disease: a cross-sectional study in North America.Preventing Atherosclerotic Cardiovascular Disease Using American College of Cardiology and American Heart Association Prevention Guidelines: Some Good News, But Caveats Remain.A novel cost-effectiveness model of prescription eicosapentaenoic acid extrapolated to secondary prevention of cardiovascular diseases in the United States.Matching Microsimulation Risk Factor Correlations to Cross-Sectional Data: The Shortest Distance Method.Treating elevated LDL cholesterol in patients with low short-term risk: Decision making at the limits of EBM.Disparities in the Quality of Cardiovascular Care Between HIV-Infected Versus HIV-Uninfected Adults in the United States: A Cross-Sectional Study.Subclinical Atherosclerosis, Statin Eligibility, and Outcomes in African American Individuals: The Jackson Heart Study.Clinical outcomes of PCSK9Is: a meta-analysis of randomized clinical trials.Cholesterol Control Among Uninsured Adults Did Not Improve From 2001-2004 to 2009-2012 as Disparities With Both Publicly and Privately Insured Adults Doubled.Cultural primer for cardiometabolic health: health disparities, structural factors, community, pathways to improvement, and clinical applications.Moderating Effects of Patient Characteristics on the Impact of Financial Incentives.When to Start a Statin Is a Preference-Sensitive Decision.Modelling total coronary heart disease burden and long-term benefit of cholesterol lowering in middle aged men with and without a history of cardiovascular disease.What's in a Number? Risk Thresholds in Different Statin Guidelines.ACC/AHA guidelines superior to ESC/EAS guidelines for primary prevention with statins in non-diabetic Europeans: the Copenhagen General Population Study.Using lower cost statins improves outcomes for normal cholesterol non-diabetic patients.
P2860
Q30235148-50B9EB3B-7AAC-4C99-9574-9311D547F3F2Q33848767-8DF80311-5B51-42CF-A29E-13E619161D61Q35793619-1C3BB800-5622-46F4-AE6D-81C00E162A2DQ36193205-46321FBA-E9F4-48CF-957E-FF777B5EF946Q36215110-605FA108-AD82-497B-BED0-F0957DCC412BQ36296597-50002439-8682-428C-ADF0-D52D3AE98A66Q36873040-EB1F56BF-3C9B-4A60-A475-808FBD3CCBC1Q37240391-D4EF0C93-69B6-4919-A684-95816585601BQ37357439-606D913F-B5AB-4389-9DC8-6EA99354B02EQ37612171-0608B9CB-B6E1-4851-9497-D2D305FE679BQ38612448-761285CC-3382-49AE-A577-568FCF4DCF05Q38631018-39B57D2C-CDB0-4E76-99B4-51230158F46EQ38650933-C1D074F0-6AF3-4491-9C04-FD05C3D3636CQ38716505-655B2457-106B-4E05-A91C-821F2A7FE7C1Q38793913-CBF9ACB1-F0B9-48FD-9B30-3D6335B9ED08Q38793991-8586748B-7A48-475B-A51D-6A157AF02418Q38828773-D7F97978-6E3D-41CD-BA63-648F1BFDB48BQ38958016-D8356225-CB29-4CC2-8205-0AEE3DBF798BQ38987368-3E4097FB-4D48-4FF0-AA51-A1F767FC40E2Q38999152-42C7E95A-58CC-4FA3-A363-4D2ADE94FFA9Q39213747-C8D26C21-239F-4ED4-A74C-BDC3BC19C3F8Q39310857-074B33A5-B061-48A0-B432-F5712696C522Q40131379-A23D6FD9-24C1-4049-B8C5-6CDDF5C4B89CQ40163250-EFBF77CC-6676-4DD6-86C4-3185D9DF42E0Q42376848-C505F82F-C503-4E4C-AE82-527DE6BD96EAQ42397109-0D1C1404-B068-4FDE-9535-E16AF4ADBEF5Q45061743-D6C9A63B-B7CF-4C34-957E-F96DC4BF53A5Q45940328-0E78E701-79D0-4E25-9337-FFEDD2629DFFQ46034210-91ADC36B-E953-43F3-99A0-9B485BBAB671Q46321167-BCE19BB4-B1EC-41EE-9875-93629E091053Q46810599-AA01FE0D-DED0-4947-8F41-781D15283D3FQ47136279-C038F71F-8E95-4E31-AFF2-30A0A9A81576Q47164852-54B7321B-4DE9-446D-AF8D-A9415D4F093AQ47567689-A51F1BD0-BA9A-4E2A-9620-9C6DED44C51AQ47580093-D53D0299-CCF6-4BE7-BFFA-E090C94A9899Q47765690-57D20D25-D274-4E43-B12B-856104623498Q47770328-AF813760-D056-4FAB-905C-A8392835B1CBQ47840754-6E02B69C-A11B-493B-987F-5B589C9F5DF5Q47908195-CD489ECD-B823-4C3A-B803-9068E3A1110EQ48145028-6D661065-BD69-4AFF-A43C-1C562CAF2F71
P2860
Cost-effectiveness of 10-Year Risk Thresholds for Initiation of Statin Therapy for Primary Prevention of Cardiovascular Disease
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Cost-effectiveness of 10-Year ...... tion of Cardiovascular Disease
@ast
Cost-effectiveness of 10-Year ...... tion of Cardiovascular Disease
@en
type
label
Cost-effectiveness of 10-Year ...... tion of Cardiovascular Disease
@ast
Cost-effectiveness of 10-Year ...... tion of Cardiovascular Disease
@en
prefLabel
Cost-effectiveness of 10-Year ...... tion of Cardiovascular Disease
@ast
Cost-effectiveness of 10-Year ...... tion of Cardiovascular Disease
@en
P2093
P2860
P356
P1476
Cost-effectiveness of 10-Year ...... tion of Cardiovascular Disease
@en
P2093
Ankur Pandya
Stephen Sy
Sylvia Cho
Thomas A Gaziano
P2860
P304
P356
10.1001/JAMA.2015.6822
P407
P577
2015-07-01T00:00:00Z